Therapeutics for Age-related Macular Degeneration (AMD)

Visgenx is developing therapeutics to protect against the loss of sight  from retinal disorders.  Our programs are based on increasing the expression of a gene known as ELOVL2  which may regulate aging in cells critical for vision.